US5246726A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Iron-containing composition and method for treatment of cancer
Assignee: Efamol Ltd
•
Filing: 1992-04-21
•
Granted: 1993-09-21
•
Expires: 2012-04-21
Abstract
Abstract Pharmaceutically acceptable compositions of one or more n-6 or n-3 essential fatty acids, particularly gamma-linolenic acid, dihomo-gamma-linolenic acid, or eicosapentaenoic acid, and assimilable iron compounds, in dosage unit form optionally with a diluent or carrier, said acids being present as such or as derivatives convertible in the body thereto and the amounts of said acids or derivatives being 1 mg to 100 g (calculated as gamma-linolenic acid) and of said iron compounds 0.1 mg to 10 g (calculated as iron) or submultiples of said amounts convenient for daily administration thereof.
Inventors
- 👤 David F. Horrobin
- 👤 Michel E. Begin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 14:17
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K31/20; A61K31/21; A61K31/215; A61K31/22; A61K31/23; A61K33/00; A61K33/24; A61K33/26
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
90 words
A method of treating cancers sensitive to treatment with an essential fatty acid selected from gamma-linolenic acid, dihomo-gamma linolenic acid, 20:5 delta-5,8,11,14,17 eicosapentaenoic acid and 22:6 delta-4,7,10,13,16,19 docosahexaenoic acid or combinations thereof in an amount of 1 mg to 100 g daily and an assimilable iron compound capable of damaging cancer cells, comprising administering to a person requiring such treatment said combination of selected essential fatty acid(s) as such or the molar equivalent of compound(s) convertible in the body thereto, and a therapeutically effective, non-toxic amount of said iron compound.
Claim 2
Independent Claim
90 words
A method of treating cancers sensitive to treatment with an essential fatty acid selected from gamma-linolenic acid, dihomo-gamma linolenic acid, 20:5 delta-5,8,11,14,17 eicosapentaenoic acid and 22:6 delta-4,7,10,13,16,19 docosahexaenoic acid or combinations thereof in an amount of 1 mg to 100 g daily and an assimilable iron compound capable of damaging cancer cells, comprising administering to a person requiring such treatment said combination of selected essential fatty acid(s) as such or the molar equivalent of compound(s) convertible in the body thereto, and a therapeutically effective, non-toxic amount of said iron compound.
Claim 3
Dependent Claim
30 words
The method according to claim 1, in which the amounts of said iron are 5 mg to 500 mg and of said acid is 50 mg to 10 g daily.
Claim 4
Dependent Claim
19 words
The method of claim 2 in which said essential fatty acid is gamma-linolenic acid, dihomo-gamma-linolenic acid or eicosapentaenoic acid.
Claim 5
Independent Claim
94 words
A method of treating cancers sensitive to treatment with the combination of gamma-linolenic acid, dihomo-gamma-linolenic acid or both in an amount of 1 mg to 100 g daily and an assimilable iron compound capable of damaging cancer cells in an amount of 0.1 mg to 1 g, calculated as iron, daily, comprising administering to a person requiring such treatment said combination of gamma-linolenic acid, dihomo-gamma-linolenic acid or both, as such or as the molar equivalent amount of a compound convertible in the body thereto, and a therapeutically effective, non-toxic amount of said iron compound.
Claim 6
Independent Claim
94 words
A method of treating cancers sensitive to treatment with the combination of gamma-linolenic acid, dihomo-gamma-linolenic acid or both in an amount of 1 mg to 100 g daily and an assimilable iron compound capable of damaging cancer cells in an amount of 0.1 mg to 1 g, calculated as iron, daily, comprising administering to a person requiring such treatment said combination of gamma-linolenic acid, dihomo-gamma-linolenic acid or both, as such or as the molar equivalent amount of a compound convertible in the body thereto, and a therapeutically effective, non-toxic amount of said iron compound.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-09-20 | 1997-03-22 | 1997-09-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-09-20 | 2001-03-22 | 2001-09-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-09-20 | 2005-03-22 | 2005-09-21 | $7700.00 | Window Closed / Lapsed |